Evidence map›Paper›PMID 36745330›Full record

ArticleCellular oncology (Dordrecht, Netherlands)2023

In-depth quantitative proteomics analysis revealed C1GALT1 depletion in ECC-1 cells mimics an aggressive endometrial cancer phenotype observed in cancer patients with low C1GALT1 expression.

Ana Montero-Calle, Álvaro López-Janeiro, Marta L Mendes, Daniel Perez-Hernandez, Irene Echevarría, Ignacio Ruz-Caracuel, Victoria Heredia-Soto, Marta Mendiola, David Hardisson, Pablo Argüeso and 3 more

Open access · hybridAbstract read
In one paragraph

Article in Cellular oncology (Dordrecht, Netherlands), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Protein Microarray Analysis with GenePix.Methods in molecular biology (Clifton, N.J.) · 2025
    Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 8 institutions in 3 countries.

Ana Montero-CalleChronic Disease Programme, UFIEC, Instituto de Salud Carlos III, 28220, Majadahonda, Madrid, Spain.
Álvaro López-JaneiroDepartment of Pathology, Hospital Universitario La Paz, 28046, Madrid, Spain.
Marta L MendesDepartment of Infection and Immunity, Luxembourg Institute of Health, 1445, Strassen, Luxembourg.
Daniel Perez-HernandezDepartment of Infection and Immunity, Luxembourg Institute of Health, 1445, Strassen, Luxembourg.
Irene EchevarríaChronic Disease Programme, UFIEC, Instituto de Salud Carlos III, 28220, Majadahonda, Madrid, Spain.
Ignacio Ruz-CaracuelDepartment of Pathology, Hospital Universitario La Paz, 28046, Madrid, Spain.
Victoria Heredia-SotoTranslational Oncology, La Paz University Hospital (IdiPAZ), 28046, Madrid, Spain.
Marta MendiolaCenter for Biomedical Research in the Cancer Network (Centro de Investigación Biomédica en Red de Cáncer, CIBERONC), Instituto de Salud Carlos III, 28046, Madrid, Spain.
David HardissonDepartment of Pathology, Hospital Universitario La Paz, 28046, Madrid, Spain.
Pablo ArgüesoTufts Medical Center, Tufts University School of Medicine, Boston, Massachusetts, USA.
Alberto Peláez-GarcíaMolecular Pathology and Therapeutic Targets Group, La Paz University Hospital (IdiPAZ), 28046, Madrid, Spain. alberto.pelaez@idipaz.es.
Ana Guzman-AranguezBiochemistry and Molecular Biology Department, Facultad de Óptica y Optometría, Universidad Complutense de Madrid, 28037, Madrid, Spain. aguzman@opt.ucm.es.
Rodrigo BarderasChronic Disease Programme, UFIEC, Instituto de Salud Carlos III, 28220, Majadahonda, Madrid, Spain. r.barderasm@isciii.es.
Hospital Universitario La Paz · ESInstituto de Salud Carlos III · ESLuxembourg Institute of Health · LUUniversidad Complutense de Madrid · ESCentro de Investigación Biomédica en Red de Cáncer · ESHospital La Paz Institute for Health Research · ESTufts University · USUnidad Funcional de Investigación de Enfermedades Crónicas · ES

Funding

AES-ISCIII PI17/01723AES-ISCIII PI20CIII/00019Ministerio de Educación, Cultura y Deporte FPU predoctoral contract to A.M-C.
6 · The paper itself

Abstract

backgroundEndometrial cancer (EC) is the most common cancer of the female reproductive organs. Despite the good overall prognosis of most low-grade ECs, FIGO I and FIGO II patients might experience tumor recurrence and worse prognosis. The study of alterations related to EC pathogenesis might help to get insights into underlying mechanisms involved in EC development and progression.

methodsCore tumoral samples were used to investigate the role of C1GALT1 in EC by immunohistochemistry (IHC). ECC-1 cells were used as endometrioid EC model to investigate the effect of C1GALT1 depletion using C1GALT1 specific shRNAs. SILAC quantitative proteomics analyses and cell-based assays, PCR, qPCR, WB, dot-blot and IHC analyses were used to identify, quantify and validate dysregulation of proteins.

resultsLow C1GALT1 protein expression levels associate to a more aggressive phenotype of EC. Out of 5208 proteins identified and quantified by LC-MS/MS, 100 proteins showed dysregulation (log

conclusionC1GALT1 stably depleted ECC-1 cells mimic an EC aggressive phenotype observed in patients and might be useful for the identification and validation of EC markers of progression.

Indexed as

Endometrial NeoplasmsProteomicsChromatography, LiquidFemaleGalactosyltransferasesGlycosylationHumansPhenotypeTandem Mass SpectrometryC1GALT1 protein, humanGalactosyltransferasesC1GALT1Endometrial cancerO-glycosylationQuantitative proteomicsSILAC

Identifiers

PMID36745330
PMCPMC10205863
OpenAlexW4319293637

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.